1h Free Analyst Time
The Nucleic Acid Therapeutics CDMO Market grew from USD 9.69 billion in 2023 to USD 10.58 billion in 2024. It is expected to continue growing at a CAGR of 9.64%, reaching USD 18.47 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The Nucleic Acid Therapeutics CDMO market, encompassing Contract Development and Manufacturing Organizations that specialize in nucleic acid-based therapies, is a rapidly evolving sector within the biopharmaceutical industry. The necessity for these CDMOs stems from the growing demand for specialized expertise and infrastructure pivotal for the development and production of nucleic acid therapeutics, which include therapies for gene silencing, gene modulation, and the introduction of corrective genes. Key applications are found in personalized medicine, targeted therapies for genetic disorders, cancer treatments, and vaccines, particularly mRNA-based solutions. End-use sectors include pharmaceutical companies, biotech firms, and research institutions. Market growth is spurred by technological advancements in gene editing tools like CRISPR, increased prevalence of genetic disorders, and significant investment in biopharma R&D. Opportunities abound in the development of scalable manufacturing platforms, enhancing delivery systems to improve cell targeting, and expanding into emerging markets with unmet healthcare needs.
However, the market faces limitations such as high capital costs, stringent regulatory requirements, and complex intellectual property landscapes. These challenges necessitate innovation in cost-effective production technologies and navigating the regulatory maze efficiently. Key areas of innovation include improving nucleic acid stability and delivery mechanisms, developing robust manufacturing processes, and fostering collaborations for technology sharing. The nature of the market is competitive yet collaborative, with a focus on research partnerships and licensing agreements to advance technology and therapeutic reach. Strategic recommendations for businesses include investing in state-of-the-art production facilities, forming strategic alliances to enhance service offerings, and monitoring regulatory changes to swiftly adapt operations. The CDMO market's future rests on leveraging breakthroughs in precision medicine, optimizing supply chains, and aligning with digital advancements like AI and data analytics for process optimization and predictive insights, providing a blueprint for sustainable growth and innovation.
Understanding Market Dynamics in the Nucleic Acid Therapeutics CDMO Market
The Nucleic Acid Therapeutics CDMO Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Growing prevalence of genetic disorders worldwide
- Increasing funding and investments support nucleic acid research
- Market Restraints
- High production costs of nucleic acid therapies
- Market Opportunities
- Rising regulatory approvals for nucleic acid therapies
- High potential with the expansion of personalized medicine
- Market Challenges
- Limited scalability of nucleic acid therapies
Exploring Porter’s Five Forces for the Nucleic Acid Therapeutics CDMO Market
Porter’s Five Forces framework further strengthens the insights of the Nucleic Acid Therapeutics CDMO Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Nucleic Acid Therapeutics CDMO Market
External macro-environmental factors deeply influence the performance of the Nucleic Acid Therapeutics CDMO Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Nucleic Acid Therapeutics CDMO Market
The Nucleic Acid Therapeutics CDMO Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Nucleic Acid Therapeutics CDMO Market
The Nucleic Acid Therapeutics CDMO Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Nucleic Acid Therapeutics CDMO Market
The Nucleic Acid Therapeutics CDMO Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Rentschler Biopharma SE, Sanofi SA, The Scripps Research Institute, Univercells Group, and WuXi AppTec Co., Ltd..Market Segmentation & Coverage
This research report categorizes the Nucleic Acid Therapeutics CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- DNA Therapeutics
- RNA Therapeutics
- Service
- Analytical and Quality Control Services
- Manufacturing Services
- Process Development and Optimization
- Application
- Genetic Disorders
- Infectious Diseases
- Oncology
- End-user
- Biotech Companies
- Government & Academic Research Institutes
- Pharmaceutical Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of genetic disorders worldwide
5.1.1.2. Increasing funding and investments support nucleic acid research
5.1.2. Restraints
5.1.2.1. High production costs of nucleic acid therapies
5.1.3. Opportunities
5.1.3.1. Rising regulatory approvals for nucleic acid therapies
5.1.3.2. High potential with the expansion of personalized medicine
5.1.4. Challenges
5.1.4.1. Limited scalability of nucleic acid therapies
5.2. Market Segmentation Analysis
5.2.1. Type: Ongoing advancements in mRNA therapeutics with rising prevalence of infectious diseases
5.2.2. Application: Rising incidence of cancer push the need for innovative and effective cancer treatments
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Nucleic Acid Therapeutics CDMO Market, by Type
6.1. Introduction
6.2. DNA Therapeutics
6.3. RNA Therapeutics
7. Nucleic Acid Therapeutics CDMO Market, by Service
7.1. Introduction
7.2. Analytical and Quality Control Services
7.3. Manufacturing Services
7.4. Process Development and Optimization
8. Nucleic Acid Therapeutics CDMO Market, by Application
8.1. Introduction
8.2. Genetic Disorders
8.3. Infectious Diseases
8.4. Oncology
9. Nucleic Acid Therapeutics CDMO Market, by End-user
9.1. Introduction
9.2. Biotech Companies
9.3. Government & Academic Research Institutes
9.4. Pharmaceutical Companies
10. Americas Nucleic Acid Therapeutics CDMO Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
13.3.2. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT AND OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GOVERNMENT & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 37. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 59. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 63. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 132. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 148. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 152. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
TABLE 191. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023
Companies Mentioned
The leading players in the Nucleic Acid Therapeutics CDMO market, which are profiled in this report, include:- AGC Biologics Inc.
- Agilent Technologies, Inc.
- Ajinomoto Bio-Pharma Services
- Almac Group Ltd.
- Biomay AG
- BioSpring GmbH
- Catalent, Inc.
- Charles River Laboratories International, Inc.
- CordenPharma International GmbH
- Creative Biogene
- Danaher Corporation
- Eurofins Scientific SE
- Evonik Industries AG
- GenScript Biotech Corporation
- Lonza Group Ltd.
- Polypeptide Group AG
- Rentschler Biopharma SE
- Sanofi SA
- The Scripps Research Institute
- Univercells Group
- WuXi AppTec Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 190 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 10.58 Billion |
| Forecasted Market Value ( USD | $ 18.47 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
